MedEquities Realty Trust (MRT) Expected to Post Quarterly Sales of $16.93 Million

Equities research analysts predict that MedEquities Realty Trust (NYSE:MRT) will post $16.93 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for MedEquities Realty Trust’s earnings, with the lowest sales estimate coming in at $16.76 million and the highest estimate coming in at $17.10 million. MedEquities Realty Trust posted sales of $14.83 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 14.2%. The company is scheduled to announce its next quarterly earnings results on Tuesday, August 14th.

On average, analysts expect that MedEquities Realty Trust will report full year sales of $69.09 million for the current year, with estimates ranging from $69.07 million to $69.10 million. For the next financial year, analysts anticipate that the company will report sales of $77.99 million per share, with estimates ranging from $76.40 million to $79.58 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow MedEquities Realty Trust.

MedEquities Realty Trust (NYSE:MRT) last posted its quarterly earnings results on Thursday, May 10th. The financial services provider reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.30 by ($0.14). MedEquities Realty Trust had a net margin of 34.63% and a return on equity of 6.17%. The business had revenue of $16.72 million for the quarter, compared to analysts’ expectations of $16.41 million.

A number of analysts have recently weighed in on MRT shares. Royal Bank of Canada reiterated a “sector perform” rating and set a $11.00 target price (down from $12.00) on shares of MedEquities Realty Trust in a report on Wednesday, May 23rd. B. Riley set a $13.00 target price on shares of MedEquities Realty Trust and gave the stock a “buy” rating in a report on Monday, May 14th. JMP Securities set a $13.00 target price on shares of MedEquities Realty Trust and gave the stock a “buy” rating in a report on Friday, May 11th. ValuEngine lowered shares of MedEquities Realty Trust from a “hold” rating to a “sell” rating in a report on Wednesday, May 2nd. Finally, KeyCorp dropped their target price on shares of MedEquities Realty Trust from $13.00 to $12.00 and set an “overweight” rating for the company in a report on Monday, April 16th. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the stock. MedEquities Realty Trust currently has an average rating of “Hold” and an average target price of $12.25.

In other news, Director Bluemountain Capital Managemen sold 11,401 shares of the stock in a transaction dated Friday, May 25th. The shares were sold at an average price of $10.35, for a total transaction of $118,000.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders have sold 353,740 shares of company stock valued at $3,653,408. 3.00% of the stock is currently owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. LSV Asset Management bought a new position in shares of MedEquities Realty Trust during the fourth quarter valued at approximately $103,000. MetLife Investment Advisors LLC bought a new position in shares of MedEquities Realty Trust during the fourth quarter valued at approximately $120,000. Barclays PLC increased its stake in shares of MedEquities Realty Trust by 252.2% during the first quarter. Barclays PLC now owns 16,016 shares of the financial services provider’s stock valued at $168,000 after purchasing an additional 11,469 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of MedEquities Realty Trust by 221.9% during the first quarter. JPMorgan Chase & Co. now owns 19,898 shares of the financial services provider’s stock valued at $210,000 after purchasing an additional 13,717 shares in the last quarter. Finally, UBS Group AG increased its stake in shares of MedEquities Realty Trust by 52.3% during the first quarter. UBS Group AG now owns 23,234 shares of the financial services provider’s stock valued at $244,000 after purchasing an additional 7,978 shares in the last quarter. 93.54% of the stock is owned by institutional investors.

MedEquities Realty Trust opened at $10.54 on Thursday, according to MarketBeat. MedEquities Realty Trust has a 12-month low of $9.67 and a 12-month high of $13.06. The stock has a market cap of $329.39 million, a price-to-earnings ratio of 9.25 and a beta of -0.18.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 5th. Stockholders of record on Tuesday, May 22nd will be issued a dividend of $0.21 per share. The ex-dividend date is Monday, May 21st. This represents a $0.84 dividend on an annualized basis and a dividend yield of 7.97%. MedEquities Realty Trust’s dividend payout ratio is currently 73.68%.

About MedEquities Realty Trust

MedEquities Realty Trust (NYSE: MRT) is a self-managed and self-administered real estate investment trust that invests in a diversified mix of healthcare properties and healthcare-related real estate debt investments. The Company's management team has extensive industry experience in acquiring, owning, developing, financing, operating, leasing and monetizing many types of healthcare properties and portfolios.

Get a free copy of the Zacks research report on MedEquities Realty Trust (MRT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for MedEquities Realty Trust (NYSE:MRT)

Receive News & Ratings for MedEquities Realty Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedEquities Realty Trust and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply